ArticleCancer medicine2026
Survival of Hematologic Malignancy In Patients With Early-Stage Chronic Kidney Disease (SHIP-CKD).
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a common comorbidity among cancer patients and may influence treatment options and outcomes. However, the independent effect of CKD in patients with hematologic malignancies remains unclear.
methodsWe conducted a retrospective cohort study using electronic medical records of 1238 adult patients diagnosed with hematologic malignancies between 2015 and 2019. Patients with CKD stages 1-3A were compared to those without CKD. The primary outcome was 5-year all-cause mortality. We used stratified Cox proportional hazards models adjusted for age, sex, and comorbidities (HIV, diabetes, hypertension, and COPD) and performed 1:1 propensity score matching without replacement. Subgroup analyses by cancer subtypes were performed.
resultsAmong 1238 patients, 529 (42.7%) had CKD. CKD patients were older (67 vs. 55 years), with higher rates of hypertension (66.0% vs. 48.0%). Five-year mortality was higher in the CKD group (24.4% vs. 17.8%, p = 0.006). In adjusted Cox models, CKD was not significantly associated with mortality (HR 1.08; 95% CI: 0.82-1.43). Subgroups by stages showed no significant risk: stage 1 (HR 1.27; 95% CI: 0.76-2.13), stage 2 (HR 1.05; 95% CI: 0.77-1.43), stage 3A (HR 1.03; 95% CI: 0.60-1.78). In matched analysis (n = 758), CKD remained non-significant (HR 1.04; 95% CI: 0.77-1.41).
conclusionEarly-stage CKD was common among patients with hematologic malignancies and associated with higher unadjusted mortality, but not with increased mortality after adjusting for age, sex, and comorbidities. These findings suggest that early-stage CKD may not independently impact survival among patients with hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.